• DOI:10.1016/S1474-4422(11)70039-4
Corpus ID: 37154043

AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial

@article{Lewitt2011AAV2GADGT,
  title={AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial},
  author={P. Lewitt and A. Rezai and M. Leehey and S. Ojemann and A. Feigin and S. Tatter},
  journal={The Lancet Neurology},
  year={2011},
  volume={10},
  pages={309-319}
}

• P. Lewitt, A. Rezai, +3 authors S. Tatter
• Published 2011
• Medicine
• The Lancet Neurology

BACKGROUND Gene transfer of glutamic acid decarboxylase (GAD) and other methods that modulate production of GABA in the subthalamic nucleus improve basal ganglia function in parkinsonism in animal models. We aimed to assess the effect of bilateral delivery of AAV2-GAD in the subthalamic nucleus compared with sham surgery in patients with advanced Parkinson's disease. METHODS Patients aged 30-75 years who had progressive levodopa-responsive Parkinson's disease and an overnight off-medication… Expand

View on Elsevier

doi.org

Save to Library

Create Alert

Cite

Launch Research Feed